BACKGROUND: Previous reports demonstrate that 1-year survival is severely compromised in @entity1 with severe @entity813 ( @entity813 ) after lung transplantation. We examined if advances in extracorporeal membrane oxygenation (ECMO) support, including @entity52174 oxygenators and reliance on venovenous (VV) ECMO have improved outcomes in @entity1 with severe @entity813 after lung transplantation. METHODS: The analysis included data prospectively collected on all single-lung or double-lung transplants between November 2001 and December 2009. Heart-lung transplants were excluded. Comparisons were made between recipients who did and did not require ECMO for @entity813 after transplant. RESULTS: Since November 2001, when VV ECMO became the routine treatment for severe @entity813 after transplant at our center, 28 of 498 @entity1 (6%) have required VV ECMO support. Successful weaning occurred in 27 of 28 (96%). Support was withdrawn for 1 @entity1 with irreversible @entity16 . Survival was substantially better than in previous reports: 30 days, 82%; 1 year, 64%; and 5 years, 49%. Freedom from @entity4154 was 88% in the ECMO survivors at 3 years, but maximum allograft function was considerably worse than in transplant recipients not requiring ECMO (peak forced expiratory volume in 1 second: 58% in ECMO vs 83% in non-ECMO, p=0.001). CONCLUSIONS: Advances in ECMO technology, particularly VV ECMO, have greatly improved the ability to support @entity1 with severe @entity813 after lung transplantation. VV ECMO is an important tool in the armamentarium of any lung transplant program to optimize @entity1 outcomes; however, strategies to improve lung allograft function in @entity1 experiencing severe @entity813 are still needed.

Improved survival but marginal allograft function in XXXX treated with extracorporeal membrane oxygenation after lung transplantation.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurologic injury'] @entity52174 :: ('MESH:C021245', 'Chemical') :: ['polymethylpentene'] @entity813 :: ('MESH:D055031', 'Disease') :: ['primary graft dysfunction', 'PGD'] @entity4154 :: ('MESH:D001989', 'Disease') :: ['bronchiolitis obliterans syndrome']
@entity1 :: (9606,Species) :: ['patients']
